Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostate Cancer Metastatic 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumours 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1NSCLC Harboring NRG1 Fusion 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate-Resistant Prostate Cancer 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × enzalutamide × Clear all
NCT02605863 2018-10-03

Enzalutamide for Bladder Cancer Chemoprevention

University of Rochester

Phase 2 Terminated
1 enrolled 6 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡